Annexon Provides Inducement Grants to New Team Members
BRISBANE, Calif. – Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company dedicated to advancing innovative therapies for severe neuroinflammatory diseases, recently announced the induction of nine new non-executive employees. This initiative was executed under the 2022 Employment Inducement Award Plan, which is in line with Nasdaq Listing Rule 5635(c)(4).
Details of the Inducement Grants
The newly appointed non-executive team members collectively received options to purchase 901,000 shares of Annexon common stock. These options come with a ten-year term and have an exercise price of $4.44 per share, reflecting the closing stock price on the grant date. Vesting for these options is structured over four years, starting with 25% vesting on the first anniversary of the grant, followed by the remaining shares vesting monthly thereafter, contingent upon continued service.
Innovative Focus of Annexon
Annexon is committed to leveraging advances in neuroinflammatory research to develop potentially groundbreaking treatments for individuals suffering from various debilitating conditions. The company focuses on the classical complement system, particularly C1q, a key player in neuroinflammation that can lead to significant tissue damage. By addressing this aspect, Annexon's therapies aim to stop neuroinflammatory diseases from progressing at their source.
Therapeutic Areas and Pipeline
The company’s pipeline highlights its commitment to tackling unmet medical needs across three significant therapeutic areas: autoimmune diseases, neurodegeneration, and ophthalmic disorders. With targeted investigational drug candidates in development, Annexon seeks to provide solutions to a global population of over 8 million affected individuals.
Mission and Vision
Annexon’s mission centers around developing innovative treatments that can significantly enhance the quality of life for patients. By inventing novel immunotherapies aimed at halting diseases before they escalate, the company envisions delivering impactful solutions that resonate deeply with those affected.
Investor Relations and Contact Information
For investors and stakeholders interested in learning more about Annexon's endeavors and progress, the company encourages inquiries and communication.
Joyce Allaire
LifeSci Advisors
Contact: jallaire@lifesciadvisors.com
Frequently Asked Questions
What were the grants provided for at Annexon?
The grants were inducement options awarded to nine new non-executive employees aimed at enhancing talent within the company.
How many shares were granted to new employees?
New employees received options for a total of 901,000 shares of Annexon common stock.
What is the purpose of Annexon's focus on C1q?
Targeting C1q is aimed at addressing the root cause of neuroinflammation and preventing subsequent tissue damage.
What therapeutic areas does Annexon specialize in?
Annexon focuses on autoimmune, neurodegenerative, and ophthalmic diseases with a commitment to addressing critical unmet needs.
How can investors contact Annexon?
Investors can reach out to Joyce Allaire at LifeSci Advisors via email at jallaire@lifesciadvisors.com.
